Top

Published in:

Open Access 01-12-2015 | Research

Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review

Authors: G M O’Kane, K A Cadoo, E M Walsh, R Emerson, P Dervan, C O’Keane, B Hurson, G O’Toole, S Dudeney, E Kavanagh, S Eustace, D N Carney

Published in: Clinical Sarcoma Research | Issue 1/2015

Abstract

Background

Chemotherapy in the multimodality treatment of osteosarcoma has improved survival. Reported outcomes on adult patients are limited. Poor necrosis rates post neoadjuvant chemotherapy (NAC) is considered an adverse prognostic factor and attempts have been made to improve survival in this group.

Patients and methods

Adult and young adult patients diagnosed with osteosarcoma between January 1986 and August 2012 were retrospectively reviewed. Patients identified were stratified according to stage (localised or metastatic) and age (≤40 and >40 years). Event free survival (EFS) and overall survival (OS) outcomes were determined. In patients with localised disease ≤40 years, survival was assessed according to necrosis rates post NAC (<90 and ≥90%). NAC consisted of two cycles of methotrexate alternating with doxorubicin/cisplatin (MAP) followed by definitive surgery. Those with ≥90% tumour necrosis continued on MAP. Patients with <90% necrosis received ifosfamide and etoposide (IE) post operatively.

Results

A total of 108 patients were reviewed and 97 were included. Median age was 23 years (range 16–75) and 70% of patients were male. Five year EFS and OS across all groups was 57% and 63% respectively. Of the patients with localised disease (N = 81), 5-year overall survival (OS), with a median follow up of 7 years (2–26) was 70% (p < 0.0001). Patients aged 16–40 (N = 68) with localised osteosarcoma had a significantly improved 5-year OS (74%) compared to those >40 years (N = 13) (42%) (p = 0.004). Of the 68 patients with localised osteosarcoma ≤40 years, 62 were evaluated according to necrosis rates post MAP. In 33 patients who achieved ≥90% necrosis and continued MAP, 5-year OS was 82%. In 29 patients who had <90% tumour necrosis and received adjuvant IE, 5-year OS was 68% (p = 0.15). Multivariate analysis confirmed age and stage as prognostic factors but not poor necrosis rates in our treated population.

Conclusions

Long-term survival outcomes in a predominantly adult Irish population are similar to large reported trials. Age and stage at diagnosis are prognostic. Postoperative ifosfamide/etoposide alone in patients with poor necrosis rates is a feasible regimen, but its role in the adjuvant setting remains uncertain.

Available only for authorised users

Bielack S, Carrle D, Casali PG, Group EGW (2009) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(Suppl 4):137–139PubMed

Huvos AG (1986) Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 57(7):1442–1449PubMedCrossRef

Ottaviani G, Jaffe N (2009) The epidemiology of osteosarcoma. Cancer Treat Res 152:3–13PubMedCrossRef

Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K et al (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol Off J Am Soc Clin Oncol 20(3):776–790CrossRef

Marcove RC, Miké V, Hajek JV, Levin AG, Hutter RV (1970) Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. J Bone Joint Surg Am 52(3):411–423PubMed

Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21(8):1574–1580PubMedCrossRef

Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ et al (1997) Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol 15(1):76–84

Hogendoorn PC, Athanasou N, Bielack S, De Alava E, Dei Tos AP, Ferrari S et al (2010) Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v204–v213PubMedCrossRef

Rosen G (1985) Preoperative (neoadjuvant) chemotherapy for osteogenic sarcoma: a 10 year experience. Orthopedics 8(5):659–664PubMed

10.

Ta HT, Dass CR, Choong PF, Dunstan DE (2009) Osteosarcoma treatment: state of the art. Cancer Metastasis Rev 28(1–2):247–263PubMedCrossRef

11.

Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, Nirenberg A et al (1983) Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 106(Suppl):55–67PubMedCrossRef

12.

Bacci G, Bertoni F, Longhi A, Ferrari S, Forni C, Biagini R et al (2003) Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 97(12):3068–3075PubMedCrossRef

13.

Hauben EI, Weeden S, Pringle J, Van Marck EA, Hogendoorn PC (2002) Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. Eur J Cancer 38(9):1218–1225PubMedCrossRef

14.

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P (2006) Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 106(5):1154–1161PubMedCrossRef

15.

Smeland S, Müller C, Alvegard TA, Wiklund T, Wiebe T, Björk O et al (2003) Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders. Eur J Cancer 39(4):488–494PubMedCrossRef

16.

Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC et al (2011) Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47(16):2431–2445PubMedCrossRef

17.

Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP et al (2002) Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol Off J Am Soc Clin Oncol 20(2):426–433CrossRef

18.

Schwartz CL, Wexler LH, Devidas M, Goorin A, Grier H, Meyers P et al (2004) P9754 therapeutic intensification in non-metastatic osteosarcoma: a COG trial. In J Clin Oncol (meeting abstracts) July 2004, vol. 22, no. 14_suppl8514

19.

Marina N, Smeland S, Bielack SS, Bernstein M, Jovic G, Hook JM et al (2014) MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1 (Paper 032). Presented at Connective Tissue Oncology Society (CTOS) 2014.

20.

Simon MA, Aschliman MA, Thomas N, Mankin HJ (1986) Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am 68(9):1331–1337PubMed

21.

Rougraff BT, Simon MA, Kneisl JS, Greenberg DB, Mankin HJ (1994) Limb salvage compared with amputation for osteosarcoma of the distal end of the femur. A long-term oncological, functional, and quality-of-life study. J Bone Joint Surg Am 76(5):649–656PubMed

22.

Ries LA, Smith M, Gurney JG et al (eds) (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995

23.

Mirabello L, Troisi RJ, Savage SA (2009) International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 125(1):229–234PubMedCentralPubMedCrossRef

24.

Carsi B, Rock MG (2002) Primary osteosarcoma in adults older than 40 years. Clin Orthop Relat Res 397:53–61PubMedCrossRef

25.

Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R et al (2003) Osteosarcoma over the age of forty. Eur J Cancer 39(2):157–163PubMedCrossRef

26.

Longhi A, Errani C, Gonzales-Arabio D, Ferrari C, Mercuri M (2008) Osteosarcoma in patients older than 65 years. J Clin Oncol Off J Am Soc Clin Oncol 26(33):5368–5373CrossRef

27.

Harting MT, Lally KP, Andrassy RJ, Vaporciyan AA, Cox CS, Hayes-Jordan A et al (2010) Age as a prognostic factor for patients with osteosarcoma: an analysis of 438 patients. J Cancer Res Clin Oncol 136(4):561–570PubMedCrossRef

28.

Bacci G, Ferrari S, Donati D, Longhi A, Bertoni F, Di Fiore M et al (1998) Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep 5(5):1259–1263PubMed

29.

Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol Off J Am Soc Clin Oncol 21(10):2011–2018CrossRef

30.

Aljubran AH, Griffin A, Pintilie M, Blackstein M (2009) Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases. Ann Oncol 20(6):1136–1141PubMedCrossRef

31.

Bielack SS, Kempf-Bielack B, Branscheid D, Carrle D, Friedel G, Helmke K et al (2009) Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients. J Clin Oncol Off J Am Soc Clin Oncol 27(4):557–565CrossRef

32.

Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH et al (2005) Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10):2214–2221PubMedCrossRef

33.

Bacci G, Briccoli A, Longhi A, Ferrari S, Mercuri M, Faggioli F et al (2005) Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol 44(7):748–755PubMedCrossRef

34.

Bielack SS, Kempf-Bielack B, Winkler K (1996) Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. J Clin Oncol Off J Am Soc Clin Oncol 14(2):683–684

35.

Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2):112–128PubMedCrossRef

36.

Jaffe N, Gorlick R (2008) High-dose methotrexate in osteosarcoma: let the questions surcease—time for final acceptance. J Clin Oncol Off J Am Soc Clin Oncol 26(27):4365–4366CrossRef

37.

Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR et al (2009) International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res 152:339–353PubMedCrossRef

38.

Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM et al (2015) Methotrexate, doxorubicin, and cisplatin (map) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. doi:10.1200/JCO.2014.60.0734 PubMed

39.

Carli M, Passone E, Perilongo G, Bisogno G (2003) Ifosfamide in pediatric solid tumors. Oncology 65(Suppl 2):99–104PubMedCrossRef

40.

Ferrari S, Ruggieri P, Cefalo G, Tamburini A, Capanna R, Fagioli F et al (2012) Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol Off J Am Soc Clin Oncol 30(17):2112–2118CrossRef

41.

Bacci G, Briccoli A, Ferrari S, Longhi A, Mercuri M, Capanna R et al (2001) Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli’s 4th protocol. Eur J Cancer 37(16):2030–2039PubMedCrossRef

42.

Bruland Ø, Bauer H, Alvegaard T, Smeland S (2009) Treatment of osteosarcoma. The Scandinavian Sarcoma Group experience. Cancer Treat Res 152:309–318PubMedCrossRef

Title: Perioperative chemotherapy in the treatment of osteosarcoma: a 26-year single institution review
Authors: G M O’Kane
K A Cadoo
E M Walsh
R Emerson
P Dervan
C O’Keane
B Hurson
G O’Toole
S Dudeney
E Kavanagh
S Eustace
D N Carney
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Clinical Sarcoma Research / Issue 1/2015
Electronic ISSN: 2045-3329
DOI: https://doi.org/10.1186/s13569-015-0032-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?

Metastasizing tenosynovial giant cell tumour, diffuse type/pigmented villonodular synovitis

Hormonal treatments in metastatic endometrial stromal sarcomas: the 10-year experience of the sarcoma unit of Royal Marsden Hospital

Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation

Presentation and management of pulmonary artery sarcoma

Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT

Keynote webinar | Spotlight on antibody–drug conjugates in cancer